Allan Reine
CIK 1714023 · Chief Executive Officer · last filed 2026-02-27
Allan Reine is a Chief Executive Officer who has filed 18 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for PRME, was dated Feb 27, 2026. Across all open-market trades the lifetime net is +$460.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $571.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$571.7K
3
18
$460.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Chief Executive Officer | 125,000 | $2.77 | $346.9K | $147.2K | 9 | 2026-02-27 |
| FHTX | Chief Financial Officer | 53,784 | $4.18 | $224.8K | $0 | 5 | 2024-01-17 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Chief Financial Officer | 45,000 | $13.60 | $612.0K | $313.4K | 4 | 2019-02-28 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-27 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-08-05 | PRME | Mixed | — | $0 | EDGAR |
| 2025-05-22 | PRME | Buy (P) | +125,000 | $147.2K | EDGAR |
| 2025-05-19 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-05-12 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-03-03 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-12-09 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-01-19 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-01-17 | FHTX | — | — | $0 | EDGAR |